Avibactam is a non-β-lactam β-lactamase inhibitor developed by Actavis (now Allergan) jointly with AstraZeneca. A new drug application for avibactam in combination with ceftazidime (branded as Avycaz) was approved by the FDA on February 25, 2015, for treating complicated urinary tract (cUTI) and complicated intra-abdominal infections (cIAI) caused by antibiotic resistant-pathogens, including those caused by multi-drug resistant Gram-negative bacterial pathogens.

CAS：1192500-31-4
中文别名：
英文别名：(2S,5R)-7-Oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbox amide;(E)-7-fluoro-3-methylhept-4-en-2-one;trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;4-Hepten-2-one,7-fluoro-3-methyl-,(E);trans-7-fluoro-3-methyl-4-hepten-2-one;
分子式：C7H11N3O6S
分子量：265.244
精确质量：265.037
Psa：139.61
Logp：0.581

密度：1.9±0.1g/cm3
折射率：1.679
储存条件：-20°C